Efficacy and Safety of Lecanemab in Treating Alzheimer's Disease: A Real‐World Study in South China
Lecanemab was generally well-tolerated and the improvements in blood biomarkers suggest that it may have a beneficial impact on disease progression.
Authors
- Haobo Chen (ORCID: https://orcid.org/0000-0002-5378-2697)
- Jipeng Ouyang (ORCID: https://orcid.org/0000-0003-2091-497X)
- Xiaoya Gao (ORCID: https://orcid.org/0000-0002-6839-817X)
- Haiqun Xie
- Liangyu Zou
- Shunjun Feng
- Bin Chen
- Qun Yu
- Feiqi Zhu
- Zhiming Li
- Yingte Wang
- Jun Liu
- Wang Liao
- Lin Han
- Ying Yang
- Zhou Liu
- Hangyu Weng
Institutions
- Foshan University (CN)
- Guangdong Medical College (CN)
- Southern University of Science and Technology (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- The First People's Hospital of Shunde (CN)
- Foshan Hospital of TCM (CN)
- Guangzhou First People's Hospital (CN)
- Zhujiang Hospital (CN)
- Dongguan People’s Hospital (CN)
- Guangdong Provincial People's Hospital (CN)
- Affiliated Hospital of Guangdong Medical College Hospital (CN)
- First Affiliated Hospital of Jinan University (CN)
- Shenzhen Second People's Hospital (CN)
- Shenzhen Third People’s Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101567
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00